337 related articles for article (PubMed ID: 11865427)
1. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
2. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
[TBL] [Abstract][Full Text] [Related]
4. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
[TBL] [Abstract][Full Text] [Related]
5. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
Marshall BC; Adler SP
Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
[TBL] [Abstract][Full Text] [Related]
6. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
[TBL] [Abstract][Full Text] [Related]
7. Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects.
Schleiss MR; Bernstein DI; Passo M; Parker S; Meric C; Verdier F; Newkirk MM
Vaccine; 2004 Dec; 23(5):687-92. PubMed ID: 15542191
[TBL] [Abstract][Full Text] [Related]
8. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.
Drulak MW; Malinoski FJ; Fuller SA; Stewart SS; Hoskin S; Duliege AM; Sekulovich R; Burke R; Winston S
Viral Immunol; 2000; 13(1):49-56. PubMed ID: 10733168
[TBL] [Abstract][Full Text] [Related]
10. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
11. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.
Axelsson F; Adler SP; Lamarre A; Ohlin M
Vaccine; 2007 Dec; 26(1):41-6. PubMed ID: 18063447
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
[TBL] [Abstract][Full Text] [Related]
13. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
14. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
15. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
Pass RF
J Clin Virol; 2009 Dec; 46 Suppl 4(Suppl 4):S73-6. PubMed ID: 19647480
[TBL] [Abstract][Full Text] [Related]
16. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
Ballou WR; Reed JL; Noble W; Young NS; Koenig S
J Infect Dis; 2003 Feb; 187(4):675-8. PubMed ID: 12599085
[TBL] [Abstract][Full Text] [Related]
18. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection.
Schleiss MR; Bourne N; Bernstein DI
J Infect Dis; 2003 Dec; 188(12):1868-74. PubMed ID: 14673766
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers.
Mitchell DK; Holmes SJ; Burke RL; Duliege AM; Adler SP
Pediatr Infect Dis J; 2002 Feb; 21(2):133-8. PubMed ID: 11840080
[TBL] [Abstract][Full Text] [Related]
20. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
